

Orthocell receives \$1,947,998 R&D tax incentive refund

Perth, Australia; 09 January 2017: Regenerative medicine company Orthocell Limited (“the Company”) is pleased to announce that it has received a Research and Development (R&D) tax incentive cash refund of \$1,947,998 for the financial year 2015/2016.

The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake research and development in Australia under which eligible companies can receive cash rebates of up to 45% of eligible expenditure on research and development activities.

ENDS

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited, Managing Director

P: +61 8 9360 2888
E: paulanderson@orthocell.com.au

Investor and Media enquiries

Ben Walsh
WE Buchan

P: + 61 411 520 012
E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

